Skip to main content
Fig. 2 | Journal of Orthopaedic Surgery and Research

Fig. 2

From: Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

Fig. 2

The magnitude of numeric rating scale (NRS) improvement after 8 weeks of treatment with mirogabalin. No significant differences were observed in the magnitude of NRS improvement in patients taking maximum doses of 5 mg/day (n = 47), 10 mg/day (n = 89), 20 mg/day (n = 32), and 30 mg/day (n = 19). Data are expressed as the mean ± standard deviation. N.S., not significant

Back to article page